| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer | Director | President & CEO
3 companies
Peter G Traber last filed a Form 4 in September 2023, as Chief Medical Officer at RNAC. The filings on record cover 3 companies. From June 2015 to September 2023, the filings on record show 6 open-market purchases and 7 sales. Peter G Traber's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Peter G Traber a middling insider score of 59/100, based on 11 past trades. Over a 12-month horizon, 54.5% of those trades were profitable, with an average 12-month return of -4.3%.
At the last filing, the largest reported position was 451,826 shares of RNAC. Net of sales, the RNAC filings show accumulation of 74,206 shares.
Shares as reported in the last Form 4 for each company; the most recent is from September 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 8, 2018 | GALT Galectin Therapeutics Inc | President & CEO | Sale+OE | 70,000 | $5.86 | $409,997.00 | -39.5% | |
| Aug 12, 2015 | GALT Galectin Therapeutics Inc | President & CEO | Buy | 2,000 | $2.00 | $4,000.00 | +1.9% | |
| Jun 1, 2015 | GALT Galectin Therapeutics Inc | President & CEO | Buy | 4,000 | $2.53 | $10,120.00 | +3.9% |